Inhaled Technosphere Insulin for Exercise-Induced Hypoglycemia in T1D
This study is looking at adults (18-65 years old) with type 1 diabetes (T1D) who use a Tandem t:slim X2 or Mobi insulin pump with Control-IQ technology. The goal is to see if using inhaled Technosphere Insulin for a meal before exercise is safer and works better than your usual rapid-acting insulin (RAA insulin) given through your pump to prevent low blood sugar (hypoglycemia) during exercise. About 30 people will join this study. Success will be measured by how often blood sugar levels drop below 70 mg/dL 90 minutes after a meal. The study is currently unclear on its recruitment status.
- Study design
- This is a randomized crossover study, meaning you will try different treatments in a random order. About 30 participants are planned to be enrolled.
- What's involved
- You will complete three exercise visits at the clinic, each following a standard lunch meal.
- Compensation
- Not stated in the trial record.
- Follow-up
- Blood glucose levels will be measured at 90 minutes after a meal during the study sessions.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Michael R Rickels, MD, MA · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
- Michael Ridell, PhD · STUDY_CHAIR · York University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- PHASE 1: Blood glucose <70 mg/dL90 minutes
Blood glucose \<70 mg/dL within 90 minutes from the start of exercise
- PHASE 2: Blood glucose <70 mg/dL90 minutes
Blood glucose \<70 mg/dL within 90 minutes from the start of exercise